SCHEMBL2030686

SCHEMBL2030686

COc1cc(C(CC(F)(F)F)(CC(F)(F)F)P(=O)(O)O)ccc1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.40
▸ CYP3A4 P08684 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ PTPN5 P54829 1/20 0.38
▸ HTT P42858 2/20 0.37
▸ PGK1 P00558 1/20 0.34
▸ PGK2 P07205 1/20 0.34
▸ CFTR P13569 1/20 0.34
▸ PTPN1 P18031 5/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ PTPRC P08575 1/20 0.33
▸ PTPN2 P17706 1/20 0.33
▸ PTPRB P23467 1/20 0.33
▸ PTPN6 P29350 1/20 0.33
▸ PTPN11 Q06124 1/20 0.33
▸ APP P05067 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029811 0.85 ALDH1A1 (0.42) ALDH1A1CYP3A4TSHRHSD17B10TDP1
SCHEMBL2033068 0.82 ALDH1A1 (0.41) ALDH1A1CYP3A4TSHRHSD17B10TDP1
SCHEMBL2029520 0.82 ALDH1A1 (0.41) ALDH1A1CYP3A4TSHRHSD17B10TDP1
SCHEMBL2030329 0.80 ALDH1A1 (0.40) ALDH1A1CYP3A4TDP1PTPN5L3MBTL1
SCHEMBL568623 0.72 L3MBTL1 (0.56) ALDH1A1CYP3A4TSHRHSD17B10TDP1
SCHEMBL29811663 0.72 L3MBTL1 (0.56) ALDH1A1CYP3A4TSHRHSD17B10TDP1
SCHEMBL2030322 0.72 ALDH1A1 (0.49) ALDH1A1TSHRHSD17B10TDP1L3MBTL1
SCHEMBL7097334 0.70 ALDH1A1 (0.48) ALDH1A1CYP3A4TSHRHSD17B10TDP1
SCHEMBL5355009 0.70 ALDH1A1 (0.52) ALDH1A1CYP3A4TSHRHSD17B10TDP1
SCHEMBL13523944 0.68 ALDH1A1 (0.53) ALDH1A1CYP3A4TSHRHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 — — US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 — — US disclosed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 — — US disclosed
EP-2438056-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2012-04-11 — — EP disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
WO-2010141406-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2010-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS ALDH1A1 1117/4885CYP3A4 3332/4885TSHR 4171/4885
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS ALDH1A1 1117/4885CYP3A4 3332/4885TSHR 4171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback